Alnylam Non Current Liabilities Total from 2010 to 2025
| ALNY Stock | USD 268.46 2.56 0.94% |
Non Current Liabilities Total | First Reported 2003-12-31 | Previous Quarter 3 B | Current Value 3 B | Quarterly Volatility 1 B |
Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.5 M, Interest Expense of 149 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 12.79, Dividend Yield of 0.0 or PTB Ratio of 474. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
Alnylam | Non Current Liabilities Total |
Latest Alnylam Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Alnylam Pharmaceuticals over the last few years. It is Alnylam Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Alnylam Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 1,034,715,322 | |
| Geometric Mean | 277,606,765 | |
| Coefficient Of Variation | 125.41 | |
| Mean Deviation | 1,132,538,652 | |
| Median | 150,000,000 | |
| Standard Deviation | 1,297,597,984 | |
| Sample Variance | 1683760.5T | |
| Range | 3.1B | |
| R-Value | 0.87 | |
| Mean Square Error | 423902.3T | |
| R-Squared | 0.77 | |
| Slope | 238,387,817 | |
| Total Sum of Squares | 25256407.9T |
Alnylam Non Current Liabilities Total History
About Alnylam Pharmaceuticals Financial Statements
Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 3 B | 3.1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.